RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Karuna Therapeutics Stock

Karuna Therapeutics Revenue 2024

Karuna Therapeutics Revenue

28.13 M USD

Ticker

KRTX

ISIN

US48576A1007

WKN

A2PM5N

In 2024, Karuna Therapeutics's sales reached 28.13 M USD, a 4,201.53% difference from the 654,000 USD sales recorded in the previous year.

The Karuna Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e3.39-
2028e2.35-
2027e1.48-
2026e0.74-
2025e0.26-
2024e0.03-
20230-
20220.01-
20210.04-
2020--
2019--
2018--
2017--

Karuna Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Karuna Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Karuna Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Karuna Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Karuna Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Karuna Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Karuna Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Karuna Therapeutics’s growth potential.

Karuna Therapeutics Revenue, EBIT and net profit per share

DateKaruna Therapeutics RevenueKaruna Therapeutics EBITKaruna Therapeutics Net Income
2029e3.39 B undefined0 undefined1.32 B undefined
2028e2.35 B undefined1.27 B undefined964.14 M undefined
2027e1.48 B undefined668.16 M undefined512.97 M undefined
2026e742.78 M undefined21.15 M undefined38.73 M undefined
2025e261.14 M undefined-351.35 M undefined-314.6 M undefined
2024e28.13 M undefined-513.61 M undefined-470.4 M undefined
2023654,000 undefined-494.78 M undefined-433.68 M undefined
202210.64 M undefined-289.68 M undefined-276.34 M undefined
202136.96 M undefined-143.86 M undefined-143.81 M undefined
20200 undefined-71.82 M undefined-68.55 M undefined
20190 undefined-45.41 M undefined-43.96 M undefined
20180 undefined-14.51 M undefined-17.51 M undefined
20170 undefined-4.81 M undefined-6.03 M undefined

Karuna Therapeutics stock margins

The Karuna Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Karuna Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Karuna Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Karuna Therapeutics's sales revenue. A higher gross margin percentage indicates that the Karuna Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Karuna Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Karuna Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Karuna Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Karuna Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Karuna Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Karuna Therapeutics Margin History

Karuna Therapeutics Gross marginKaruna Therapeutics Profit marginKaruna Therapeutics EBIT marginKaruna Therapeutics Profit margin
2029e0 %0 %38.86 %
2028e0 %54.05 %41.1 %
2027e0 %45.18 %34.68 %
2026e0 %2.85 %5.21 %
2025e0 %-134.54 %-120.47 %
2024e0 %-1,825.71 %-1,672.11 %
20230 %-75,653.98 %-66,311.93 %
20220 %-2,722.56 %-2,597.18 %
20210 %-389.23 %-389.1 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Karuna Therapeutics Aktienanalyse

What does Karuna Therapeutics do?

Karuna Therapeutics Inc. is an American biotechnology company based in Boston, Massachusetts. It was founded in 2009 by Dr. Andrew Miller and Dr. Stephen Murray and specializes in the research and development of novel treatment methods for mental disorders. The history of Karuna Therapeutics begins with the recognition by the founders that there were not enough effective medications for mental disorders. They saw a great opportunity to fill this gap and help patients through their research and development of innovative therapies. The business model of Karuna Therapeutics is to develop novel medications for mental disorders that can complement or replace existing treatment methods. The company utilizes the latest scientific advancements to better understand the role of the brain and neurotransmitters in various disorders. Karuna Therapeutics specializes in the development of treatments for severe mental disorders such as schizophrenia, dementia, depression, and anxiety disorders. These disorders have a significant impact on the affected individuals, their families, and society as a whole. Patients with these disorders urgently need more effective treatment options to lead a normal life. The main focus of Karuna Therapeutics is the research and development of new therapies for mental disorders. The company collaborates closely with some of the most renowned scientists and researchers in this field to develop innovative approaches to treating central nervous system disorders. Currently, Karuna Therapeutics is developing a medication called "KarXT" for the treatment of schizophrenia and akathisia. KarXT is based on the combination of two known active substances that complement each other in a specific way to achieve improved efficacy. The medication is currently undergoing Phase III studies to assess its effectiveness and safety. Another product of Karuna Therapeutics is "KarGABA," an oral medication being developed for the treatment of anxiety disorders. The medication is based on a neurotransmitter responsible for relaxation and calming of the body. KarGABA is still in the early stages of development. Overall, Karuna Therapeutics invests a significant portion of its budget in research and development of new therapies. The company focuses on breaking down the traditional boundaries between different types of mental disorders and finding new ways to treat them. In summary, Karuna Therapeutics is an ambitious company dedicated to the research and development of new innovative treatment methods for mental disorders. The company aims to help affected patients and improve the lives of millions of people worldwide. Karuna Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Karuna Therapeutics's Sales Figures

The sales figures of Karuna Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Karuna Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Karuna Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Karuna Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Karuna Therapeutics stock

How much revenue did Karuna Therapeutics generate this year?

Karuna Therapeutics has achieved a revenue of 28.13 M USD this year.

How much was the turnover of the company Karuna Therapeutics compared to the previous year?

The revenue of Karuna Therapeutics has increased by 4,201.53% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Karuna Therapeutics?

The revenue of Karuna Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Karuna Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Karuna Therapeutics so important for investors?

The revenue of Karuna Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Karuna Therapeutics pay?

Over the past 12 months, Karuna Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karuna Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Karuna Therapeutics?

The current dividend yield of Karuna Therapeutics is .

When does Karuna Therapeutics pay dividends?

Karuna Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karuna Therapeutics?

Karuna Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Karuna Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karuna Therapeutics located?

Karuna Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karuna Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karuna Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Karuna Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Karuna Therapeutics in the year 2023?

In the year 2023, Karuna Therapeutics distributed 0 USD as dividends.

In which currency does Karuna Therapeutics pay out the dividend?

The dividends of Karuna Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Karuna Therapeutics

Our stock analysis for Karuna Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karuna Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.